

FOR IMMEDIATE RELEASE

March 26, 2007

Asahi Kasei Pharma Corporation
Eisai Co., Ltd.

**Asahi Kasei Pharma Corporation and Eisai Co., Ltd.
Signed License Agreement for Vasodilator *Eritel*[®] in Korea**

Asahi Kasei Pharma Corporation (AKP, Headquarters: Chiyoda-ku, Tokyo, President: Kei Oe) and Eisai Korea Inc. (Headquarters: Seoul, Korea, President: Cho Byoung Chic), a subsidiary of Eisai Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, President and CEO: Haruo Naito), signed a license agreement for Vasodilator *Eritel*[®] (Injectable formulation, generic name: fasudil hydrochloride). By this agreement, which was signed on March 23, 2007 by both companies, AKP will

Contacts:

Asahi Kasei Pharma Corporation

General Affairs Department

TEL: +81-3-3259-5777